Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
J&J Innovation Broadens Portfolio
by Lisa M. Jarvis
June 23, 2014
| A version of this story appeared in
Volume 92, Issue 25
Johnson & Johnson Innovation, an arm of J&J focused on early-stage research, has unveiled 12 new pacts with biotech firms and research institutions. The pacts span diseases including cancer, arthritis, dementia, and diabetes. Among the new partners is Energesis Pharmaceuticals, which is trying to treat metabolic diseases by stimulating the formation of brown fat. J&J also has taken stakes in Navitor Pharmaceuticals, which is developing modulators of the mTORC1 pathway to treat diabetes, and Rodin Therapeutics, a biotech firm developing epigenetic modulators for cognitive disorders.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter